ReviewsAblative Therapies for Locally Advanced Pancreatic CancerShah, Rupen MD; Ostapoff, Katherine T. MD; Kuvshinoff, Boris MD, MBA; Hochwald, Steven N. MD, FACSAuthor Information From the Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY. Received for publication January 14, 2017; accepted September 12, 2017. Address correspondence to: Steven N. Hochwald, MD, FACS, Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton St, Buffalo, NY 14263 (e-mail: [email protected]). The authors declare no conflict of interest. Pancreas: January 2018 - Volume 47 - Issue 1 - p 6-11 doi: 10.1097/MPA.0000000000000948 Buy Metrics Abstract The vast majority of patients who present with pancreatic adenocarcinoma have locally advanced or metastatic disease at the time of presentation without possibility of cure. Although in recent years there have been some new promising chemotherapy regimens that improve overall survival by a few months, the prognosis remains dismal. There is, however, a subset of patients who experience durable stable disease or partial responses after initial courses of chemotherapy with locally advanced disease. In these select patients, there remains interest in local ablative therapy with or without resection as a means for local control, palliation of symptoms, and possible improved survival. This review describes the techniques, complications, and expected benefits of several ablative techniques as a treatment modality for locally advanced pancreatic cancer. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.